Efficacy of Physiologically Active nutrients in the Treatment of Asthenic Disorders in Patients with Chronic Diffuse Liver Diseases

Over the period after an exacerbation of chronic liver diseases, patients often retain common symptoms (weakness or fatigue, bad mood, sleep disorder, vegetative disorders — asthenic syndrome). In the context of prevention and treatment of these symptoms, such nutraceutical products as enriched foods in the form of tablets, sachets, etc, have been increasingly attracting research attention.
Aim. To study the efficacy of the “Hepato Smart” nutraceutical product for the treatment of asthenic syndrome in outpatients suffering from chronic diffuse liver diseases with compensated function and functional disorders of the gallbladder over the period after exacerbation.
Materials and methods. The study included 50 patients, with 41 of them having completed the program. The nutraceutical product (curcumin, piperine, tanshinone IIA, choline; standardized for curcumin and choline) was assigned 1 pill 3 times a day with meals for 4 weeks. To objectify common symptoms, we used a D-FIS questionnaire (Daily Fatigue Impact Scale), a 4DSQ Four-Dimensional Symptom Questionnaire for assessing distress, depression, anxiety and somatization, and a SF-36 questionnaire for assessing the quality of life.
Results. Following 4 weeks of the “Hepato Smart” course, a statistically significant decrease in fatigue was noted by D-FIS scores (p = 0.003), as well as a decrease in the level of distress, depression, anxiety and somatization by 4DSQ scores (p = 0.005; p = 0.006; p = 0.003; p = 0.003, respectively). The quality of patients’ life according to the SF36 questionnaire also improved due to both physical and psychological components (p = 0.003). 16 patients continued taking the preparation for another 8 weeks to maintain the achieved result. As an additional effect, the disappearance of pain in the right hypochondrium was noted in those cases when patients presented this complaint at the time of inclusion in the observation program. The safety profile was good, 1/3 of the patients noted the appearance of heartburn, which was eliminated when taking the product with food.
Conclusion. The “Hepato Smart” nutraceutical product improves the general condition of patients with chronic diffuse liver diseases and functional disorders of the gallbladder due to a significant reduction in fatigue and anxiety. It also improves the quality of patients’ life due to the physical and mental components of health. 

1. Ivashkin V.T., Maevskaya M.V., Kobalava Z.D., Uspenskiy Y.P., Fominih J.A., Rozanov A.V. et al. Openlabel study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. Minerva Gastroenterol Dietol. 2018;64(3):208–19. DOI: 10.23736/S1121-421X.18.02461-3

2. Santini A., Cammarata S.M., Capone G. et al. Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018;84(4):659–672. DOI: 10.1111/bcp.13496

3. Mayevskaya M.V., Ivashkin V.T., Lunkov V.D., Kryzhanovskiy S.P., Pirogova I.Y., Pavlov C.S., Zharkova M.S., Beniashvili A.G., Morozova M.A. Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program). Russ J Gastroenterol Hepatol Coloproctol. 2018;28(5):77–97 (In Russ.) DOI: 10.22416/1382-4376-2018-28-5-77-97

4. Virukalpattigopalratnam M.P., Singh T., Ravishankar A.C. Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India. J lndian Med Assoc. 2013;111(12):856–9.

5. Ivashkin V.T., Maevskaya M.V., Kobalava Z.D., Uspenskiy Y.P., Fominih J.A., Rozanov A.V. et al. Openlabel study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. Minerva Gastroenterol Dietol. 2018;64(3):208–19. DOI: 10.23736/S1121-421X.18.02461-3

6. http://fp.crc.ru RU.77.99.11.003.Е.000793.02.17 от 17.02.2017

7. DeFelice S.L. The nutraceutical revolution: its impact on food industry R&D. Trends Food Sci Technol 1995;6(2):59–61.

8. Virukalpattigopalratnam M.P., Singh T., Ravishankar A.C. Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India. J lndian Med Assoc. 2013;111(12):856–9.

9. Wu A., Noble E.E., Tyagi E., Ying Z., Zhuang Y., Gomez-Pinilla F. Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders. Biochim Biophys Acta. 2015;1852(5):951–61. DOI: 10.1016/j.bbadis.2014.12.005

10. Santini A., Cammarata S.M., Capone G. et al. Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018;84(4):659–672. DOI: 10.1111/bcp.13496

11. Ng Q.X., Koh S.S.H., Chan H.W., Ho C.Y.X. Clinical Use of Curcumin in Depression: A Meta-Analysis. J Am Med Dir Assoc. 2017;18(6):503–8. DOI: 10.1016/j.jamda.2016.12.071

12. DeFelice S.L. The nutraceutical revolution: its impact on food industry R&D. Trends Food Sci Technol 1995;6(2):59–61.

13. http://fp.crc.ru RU.77.99.11.003.Е.000793.02.17 от 17.02.2017

14. Santini A., Cammarata S.M., Capone G. et al. Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018;84(4):659–672. DOI: 10.1111/bcp.13496

15. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6.

16. Wu A., Noble E.E., Tyagi E., Ying Z., Zhuang Y., Gomez-Pinilla F. Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders. Biochim Biophys Acta. 2015;1852(5):951–61. DOI: 10.1016/j.bbadis.2014.12.005

17. http://fp.crc.ru RU.77.99.11.003.Е.000793.02.17 от 17.02.2017

18. Shi M.J., Dong B.S., Yang W.N., Su S.B., Zhang H. Preventive and therapeutic role of Tanshinone II A in hepatology. Biomed Pharmacother. 2019;112:108676. DOI: 10.1016/j.biopha.2019.108676

19. Ng Q.X., Koh S.S.H., Chan H.W., Ho C.Y.X. Clinical Use of Curcumin in Depression: A Meta-Analysis. J Am Med Dir Assoc. 2017;18(6):503–8. DOI: 10.1016/j.jamda.2016.12.071

20. Mehedint M.G., Zeisel S.H. Choline’s role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16(3):339–45. DOI: 10.1097/MCO.0b013e3283600d46

21. Wu A., Noble E.E., Tyagi E., Ying Z., Zhuang Y., Gomez-Pinilla F. Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders. Biochim Biophys Acta. 2015;1852(5):951–61. DOI: 10.1016/j.bbadis.2014.12.005

22. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6.

23. Ng Q.X., Koh S.S.H., Chan H.W., Ho C.Y.X. Clinical Use of Curcumin in Depression: A Meta-Analysis. J Am Med Dir Assoc. 2017;18(6):503–8. DOI: 10.1016/j.jamda.2016.12.071

24. Fisk J.D., Doble S.E. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002 ;11(3):263–72.

25. Shi M.J., Dong B.S., Yang W.N., Su S.B., Zhang H. Preventive and therapeutic role of Tanshinone II A in hepatology. Biomed Pharmacother. 2019;112:108676. DOI: 10.1016/j.biopha.2019.108676

26. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6.

27. Terluin B., van Marwijk H.W., Adèr H.J., de Vet H.C., Penninx B.W., Hermens M.L., van Boeijen C.A., van Balkom A.J., van der Klink J.J., Stalman W.A. The Four-Dimensional Symptom Questionnaire (4DSQ): a validation study of a multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization. BMC Psychiatry. 2006:6;34. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590008/

28. Mehedint M.G., Zeisel S.H. Choline’s role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16(3):339–45. DOI: 10.1097/MCO.0b013e3283600d46

29. Shi M.J., Dong B.S., Yang W.N., Su S.B., Zhang H. Preventive and therapeutic role of Tanshinone II A in hepatology. Biomed Pharmacother. 2019;112:108676. DOI: 10.1016/j.biopha.2019.108676

30. Yakhno N.N., Smulevich A.B., Terluin B., Reikhart D.V., Zakharova E.K., Andryushchenko A.V., Parfenov V.A., Zamegrad M.V., Arnautov V.С. Primary screening of patients suffering from autonomic (vegetative) disorders in the context of everyday outpatient neurological practice of the Russian Federation (START 1): the use of the Russian-language version of the 4DSQ four-dimensional symptoms questionnaire of distress, depression, anxiety and somatization. Journal of Neurology and Psychiatry. 2014;12:112-22 (in Russ.).

31. Fisk J.D., Doble S.E. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002 ;11(3):263–72.

32. SF36. URL: http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html

33. Mehedint M.G., Zeisel S.H. Choline’s role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16(3):339–45. DOI: 10.1097/MCO.0b013e3283600d46

34. Terluin B., van Marwijk H.W., Adèr H.J., de Vet H.C., Penninx B.W., Hermens M.L., van Boeijen C.A., van Balkom A.J., van der Klink J.J., Stalman W.A. The Four-Dimensional Symptom Questionnaire (4DSQ): a validation study of a multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization. BMC Psychiatry. 2006:6;34. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590008/

35. Morozova M.A., Rupchev G.Y., Alekseyev A.A., Beniashvili A.G., Mayevskaya M.V., Poluektova Y.A., Okhlobystina O.Z., Ivashkin V.T. Dysphoric spectrum of emotional disorders at irritable bowel syndrome. Rus J Gastroenterol, Hepatol Coloproctol. 2017;27(1):12–22 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-12-22

36. Fisk J.D., Doble S.E. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002 ;11(3):263–72.

37. Yakhno N.N., Smulevich A.B., Terluin B., Reikhart D.V., Zakharova E.K., Andryushchenko A.V., Parfenov V.A., Zamegrad M.V., Arnautov V.С. Primary screening of patients suffering from autonomic (vegetative) disorders in the context of everyday outpatient neurological practice of the Russian Federation (START 1): the use of the Russian-language version of the 4DSQ four-dimensional symptoms questionnaire of distress, depression, anxiety and somatization. Journal of Neurology and Psychiatry. 2014;12:112-22 (in Russ.).

38. Motterlini R., Foresti R., Bassi R., Green C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28(8):1303–12.

39. Terluin B., van Marwijk H.W., Adèr H.J., de Vet H.C., Penninx B.W., Hermens M.L., van Boeijen C.A., van Balkom A.J., van der Klink J.J., Stalman W.A. The Four-Dimensional Symptom Questionnaire (4DSQ): a validation study of a multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization. BMC Psychiatry. 2006:6;34. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590008/

40. SF36. URL: http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html

41. Yakhno N.N., Smulevich A.B., Terluin B., Reikhart D.V., Zakharova E.K., Andryushchenko A.V., Parfenov V.A., Zamegrad M.V., Arnautov V.С. Primary screening of patients suffering from autonomic (vegetative) disorders in the context of everyday outpatient neurological practice of the Russian Federation (START 1): the use of the Russian-language version of the 4DSQ four-dimensional symptoms questionnaire of distress, depression, anxiety and somatization. Journal of Neurology and Psychiatry. 2014;12:112-22 (in Russ.).

42. Joe B., Vijaykumar M., Lokesh B.R. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44:97–111.

43. Morozova M.A., Rupchev G.Y., Alekseyev A.A., Beniashvili A.G., Mayevskaya M.V., Poluektova Y.A., Okhlobystina O.Z., Ivashkin V.T. Dysphoric spectrum of emotional disorders at irritable bowel syndrome. Rus J Gastroenterol, Hepatol Coloproctol. 2017;27(1):12–22 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-12-22

44. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr. 2007;47(8):735–48.

45. SF36. URL: http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html

46. Motterlini R., Foresti R., Bassi R., Green C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28(8):1303–12.

47. Morozova M.A., Rupchev G.Y., Alekseyev A.A., Beniashvili A.G., Mayevskaya M.V., Poluektova Y.A., Okhlobystina O.Z., Ivashkin V.T. Dysphoric spectrum of emotional disorders at irritable bowel syndrome. Rus J Gastroenterol, Hepatol Coloproctol. 2017;27(1):12–22 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-12-22

48. Yin Y., Huang L., Liu Y., Huang S., Zhuang J., Chen X., Zhang L., Wu H., Shao F., Zhao Z. Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer’s disease ratmodel. Clin Invest Med. 2008;31(5):E248–57.

49. Joe B., Vijaykumar M., Lokesh B.R. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44:97–111.

50. Motterlini R., Foresti R., Bassi R., Green C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28(8):1303–12.

51. Jiang P., Li C., Xiang Z., Jiao B. Tanshinone IIA reduces the risk of Alzheimer’s disease by inhibiting iNOS, MMP‑2 and NF‑κBp65 transcription and translation in the temporal lobes of rat models of Alzheimer’s disease. Mol Med Rep. 2014;10(2):689–94.

52. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr. 2007;47(8):735–48.

53. Joe B., Vijaykumar M., Lokesh B.R. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44:97–111.

54. Yin Y., Huang L., Liu Y., Huang S., Zhuang J., Chen X., Zhang L., Wu H., Shao F., Zhao Z. Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer’s disease ratmodel. Clin Invest Med. 2008;31(5):E248–57.

55. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr. 2007;47(8):735–48.

56. Jiang P., Li C., Xiang Z., Jiao B. Tanshinone IIA reduces the risk of Alzheimer’s disease by inhibiting iNOS, MMP‑2 and NF‑κBp65 transcription and translation in the temporal lobes of rat models of Alzheimer’s disease. Mol Med Rep. 2014;10(2):689–94.

57. Yin Y., Huang L., Liu Y., Huang S., Zhuang J., Chen X., Zhang L., Wu H., Shao F., Zhao Z. Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer’s disease ratmodel. Clin Invest Med. 2008;31(5):E248–57.

58. Jiang P., Li C., Xiang Z., Jiao B. Tanshinone IIA reduces the risk of Alzheimer’s disease by inhibiting iNOS, MMP‑2 and NF‑κBp65 transcription and translation in the temporal lobes of rat models of Alzheimer’s disease. Mol Med Rep. 2014;10(2):689–94.